Safety and Efficacy of Nabilone in Alzheimer's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2019

Conditions
Alzheimer DiseaseAgitationWeight LossPainOxidative Stress
Interventions
DRUG

Nabilone

Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).

DRUG

Placebo

Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER

NCT02351882 - Safety and Efficacy of Nabilone in Alzheimer's Disease | Biotech Hunter | Biotech Hunter